Third member of FDA advisory panel resigns over Alzheimer's drug approval

The resignations are in protest over the agency's decision to approve Biogen Inc's Alzheimer's treatment despite the committee's recommendation against doing so.
Market Update
SENSEX 31,622.48 -187.07(%)
NIFTY 9,898.00 -54.2(%)

Top News